Affiliation:
1. Scientific Centre on Expertise of Medicinal Application Products, Moscow
Abstract
The paper presents the data on the assessment of the demand for heterologous drugs and highlights the need for their use in practical healthcare. Currently, 15 heterologous immunoglobulins and sera are registered in the Russian Federation. Nine of them are against bacterial and viral infections (anthrax, diphtheria, tetanus, botulism, rabies, anti-gangrenous), one – against snake venom, five other – anti-thymocyte immunoglobulins produced by domestic and foreign manufacturers. Analysis of the data has demonstrated that anti-rabies immunoglobulin, anti-diphtheria and anti-botulinic sera, A, B and E type are the most in-demand. Production of other therapeutic drugs from this group, for instance, anti-gangrenous serum, tends to decline. Adequate provision of medical curative and preventive institutions with these preparations is a significant element in timely treatment of infectious diseases such as anthrax, diphtheria, tetanus, botulism, rabies, as well as snake bites. In prophylaxis and treatment of certain diseases (emergency aid in case of anthrax, rabies, venomous snake bites) heterologous preparations still oftentimes do not have an alternative. The key problem in regulation of heterologous preparation circulation is absence of quality, efficacy and safety criteria applicable to other immunobiological preparations. Development of unified requirements to standardization of heterologous sera and immunoglobulins of various specificity, principles of efficacy and safety evaluation is necessary for harmonization of current guidelines on medical use. Earlier elaborated by WHO approaches to heterologous sera to venoms of snakes can be used for monitoring and harmonization of normative legal documents on the improvement, evaluation of quality, efficacy and safety of alternative drugs being in circulation in the pharmaceutical market of the Russian Federation.
Publisher
Russian Research Anti-Plague Institute Microbe
Subject
Infectious Diseases,Microbiology (medical),Immunology,Microbiology,Epidemiology
Reference34 articles.
1. Arzumanov S.V., Tiptsov D.V., Mitish A.E., Gramotnev A.K. [Experience in application of various protocols for the induction treatment with depleting antibodies in case of kidney transplantation]. Transplantalogiya.2015; 2:14–9.
2. [Instructions and methodological recommendations on laboratory, clinical diagnostics, prevention and treatment of anthrax in humans]. M.; 1980. 64 p.
3. Kolesnikov A.V., Ryabko A.K., Shemyakin I.G., Kozyr’ A.V. [Modern approaches to the development of specific treatment of particularly dangerous toxicoinfections]. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk (RAMS Bulletin). 2015; 70(4):428–34. DOI: 10.15690/vramn.v70.i4.1408.
4. Korzhenkova M.P., Berko A.I., Malyshev N.A. [Diagnostics and treatment of toxic diphtheria. Part 1. Early diagnostics of toxic diphtheria]. Lechashchii Vrach.2009; 10:26–30.
5. Korzhenkova M.P., Sviridov V.V., Berko A.I., Malyshev N.A., Gal’vidis I.A., Yakovleva I.V., Burkin M.A. [Diagnostics and treatment of toxic diphtheria. Part 2. High-dose antidiphtheric serum in treatment of toxic from of diphtheria]. Lechashchii Vrach. 2010; 6:63–7.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献